Skip to main content
. 2018 Jun 6;47(5):1454–1464. doi: 10.1093/ije/dyy076

Figure 1.

Figure 1

Response to treatment (1a) and dropout rate for any reason (1b) as estimated in active arms grouped by probability of receiving placebo. Drugs are ordered by response and dropout rates estimated in the head-to-head trials (π = 0%). The bars and confidence intervals for ALL (all drugs) are estimated from the multivariate model after adjusting for differences between active drugs. AGOM, agomelatine; AMIT, amitriptyline; BUPR, bupropion; CITA, citalopram; DULO, duloxetine; ESCI, escitalopram; FLUO, fluoxetine; FLUV, fluvoxamine; LEVO, levomilnacipran; MILN, milnacipran; MIRT, mirtazapine; NEFA, nefazodone; PARO, paroxetine; REBO, reboxetine; SERT, sertraline; TRAZ, trazodone; VENL, venlafaxine; VORT, vortioxetine. The raw percentages are shown in Table 1 in Supplementary Appendix 3, available as Supplementary data at IJE online.